MedImmune Articles
AstraZeneca's Brilinta gains Class I in ACCF/AHA Guidelines; enters deal with Progenics
18 December 2012
Further $100 million committed to AstraZeneca’s MedImmune Ventures
29 November 2011
AgonOx partners with AstraZeneca unit for development of OX40 agonists in cancer therapy
2 November 2011
AstraZeneca/MedImmune’s tralokinumab shows positive impact on pulmonary function in patients with uncontrolled asthma
19 September 2011
PDL BioPharma to pay MedImmune $92.5 million to resolve patent disputes; Mylan debuts generic Vfend
17 February 2011
AstraZeneca unit highlights potential for MEDI-573 as inhibitor of development and progression of cancer
21 January 2011
AstraZeneca unit MedImmune in-licenses anti-inflammatory MAb from Amgen; latter’s Sensipar patent upheld
10 January 2011
AstraZeneca unit in 260 million-euro metabolic disease alliance with Evotec; disappointing Crestor patent ruling
16 December 2010
US FDA calls for additional trial of AstraZeneca/MedImmune’s RSV candidate motavizumab
31 August 2010
AstraZeneca’s MedImmune unit in licensing deal with Phylogica for antimicrobial peptide
20 August 2010
FDA Advisory Committee votes against approving MedImmune/AstraZeneca’s motavizumab for RSV
3 June 2010
Showing 1-17 of 17 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
